1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

EMA Says Clinical Data Published Supporting Extension Of Indication For Spikevax To Include Use In Adolescents Aged 12-17

01/25/2022 | 10:58am EDT

Jan 25 (Reuters) - European Medicines Agency:

* EMA PUBLISHED CLINICAL DATA SUPPORTING EXTENSION OF INDICATION FOR SPIKEVAX TO INCLUDE USE IN ADOLESCENTS AGED 12 TO 17. Further company coverage:


© Reuters 2022
All news about MODERNA, INC.
12:25pModerna's CEO Stephane Bancel to Exercise Shares, Intends to Donate Proceeds to Charity
MT
12:13pGLOBAL MARKETS LIVE : Broadcom, Airbnb, Roche, Toyota, Uber
10:48aWALL STREET STOCK EXCHANGE : Snap cut the rally short
09:26aRubius Therapeutics Names Noubar Afeyan Chairman; Shares Rise Pre-Bell
MT
09:15aTRANSCRIPT : Moderna, Inc. Presents at UBS Global Healthcare Conference, May-24-2022 09:15..
CI
08:03aMODERNA, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
07:44aModerna testing potential monkeypox vaccines
RE
06:41aModerna CEO to Exercise 2013 Option, Donate Funds to Charity
DJ
01:08aChina's bet on homegrown mRNA vaccines holds back nation
AQ
05/23MODERNA : Statement Regarding Section 1498 Motion
PU
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2022 22 069 M - -
Net income 2022 11 501 M - -
Net cash 2022 18 081 M - -
P/E ratio 2022 4,85x
Yield 2022 -
Capitalization 52 528 M 52 528 M -
EV / Sales 2022 1,56x
EV / Sales 2023 3,16x
Nbr of Employees 2 700
Free-Float 90,6%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 132,06 $
Average target price 212,69 $
Spread / Average Target 61,1%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-48.00%54 740
LONZA GROUP AG-27.15%42 618
IQVIA HOLDINGS INC.-28.41%38 497
SEAGEN INC.-13.67%25 649
ICON PUBLIC LIMITED COMPANY-30.17%17 688
CELLTRION, INC.-26.77%16 131